Alfatradiol
As of the edition of 20 October 2026, Alfatradiol is a small molecule: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Ell-Cranell
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Galderma Laboratorium
- Registered trials
- 8, 3 stopped early
- Disease areas
- Urinary and reproductive; Nervous system; Pregnancy and women's health; Bones, joints and muscles; Cancer; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 2 | 0 | 0 | 1 |
| Phase 2 | 4 | 2 | 1 | 1 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Renovo | Lead sponsor of trials | 2005 to now |
| BHR Pharma | Lead sponsor of trials | 2015 to now |